Companies · Biotechnology

CMI HOLDING Co INC

RICHARDSON · Biotechnology

Diligence memoA one-page analyst read on CMI HOLDING Co INC — recommendation, valuation, rhythm, risks.
$8.8M
Total raised · real
2
Rounds
0.1×
Latest step-up
Top 47%
Sector rank · raised
Series A
Latest stage · inferred · Tue Feb 23 2010 00:00:00 GMT+0000 (Coordinated Universal Time)

CMI HOLDING Co INC looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.12× the median modeled value of Series A Biotechnology companies in 2010–2012 (92 peers) — value vs value, same stage and era.
Dormant
  • Last raise 16.3 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

CMI HOLDING Co INC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
17.0 yr record
Peak capital year was 2009 with $8.1M across 1 filings.
Market position
ahead of 54% of Biotechnology peers
Capital scale is ahead of 54% of Biotechnology peers; modeled value is above 31% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2009: $8.1M across 1 filings.
  • Largest single filing was $8.1M on 2009-07-13.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

CMI HOLDING Co INC is one of 4291 Biotechnology companies tracked from RICHARDSON. By capital raised it ranks mid-pack (ahead of 54% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeries A · 2009-07-13 Raised $8.1M (real) Modeled valuation $294M (est)$8.1M$294MSeries A2009Series A · 2010-02-23 Raised $650K (real) Modeled valuation $23M (est)$650K$23MSeries A2010+$650KCumulative $8.8M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$8.1M · 2009
Series A extension$650K · 2010

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$23.5M
Base estimate est.
$709K
Conservative case
$127.8M
Upside case
$3.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $294.3M · 2009-07-132009Series A · modeled $23.5M · 2010-02-232010
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
6.0 yr
Elapsed time used
16.4 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
7 mo
Avg between rounds
$14.3M/yr
Capital velocity
17.0 yr
On record since
2009
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.2× above median
This company$8.8M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.1× of median
This company$650K
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 0.4× of median
This company$23.5M
Sector median$64.2M

Raised more than 54% of sector peers (real $). Modeled value above 31% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #87 of 92.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Tobira Therapeutics, Inc. · Series A Raised $23.2M · modeled $513.3M (est)Neoprobe Corp · Series A Raised $14.0M · modeled $506.1M (est)Akebia Therapeutics, Inc. · Series A Raised $25.9M · modeled $504.1M (est)Adimab, LLC · Series A Raised $13.8M · modeled $499.5M (est)Elevation Pharmaceuticals Inc · Series A Raised $27.4M · modeled $448.3M (est)Mnemosyne Pharmaceuticals Inc · Series A Raised $24.0M · modeled $445.8M (est)Macrogenics Inc · Series A Raised $12.0M · modeled $434.4M (est)Neurologica Corp · Series A Raised $17.0M · modeled $433.8M (est)Bodymedia Inc · Series A Raised $20.1M · modeled $429.9M (est)Peloton Therapeutics, Inc. · Series A Raised $13.7M · modeled $423.0M (est)Seahorse Bioscience Inc · Series A Raised $20.7M · modeled $410.2M (est)Stemgent, Inc. · Series A Raised $37.9M · modeled $408.5M (est)CMI HOLDING Co INC (this company) Raised $8.8M · modeled $23.5M (est)CMI HOLDING Co INC
CompanyStageRaised · realValue · estvs peer med.
Tobira Therapeutics, Inc.Series A$23.2M$513.3M2.56×
Neoprobe CorpSeries A$14.0M$506.1M2.53×
Akebia Therapeutics, Inc.Series A$25.9M$504.1M2.52×
Adimab, LLCSeries A$13.8M$499.5M2.50×
Elevation Pharmaceuticals IncSeries A$27.4M$448.3M2.24×
Mnemosyne Pharmaceuticals IncSeries A$24.0M$445.8M2.23×
Macrogenics IncSeries A$12.0M$434.4M2.17×
Neurologica CorpSeries A$17.0M$433.8M2.17×
Bodymedia IncSeries A$20.1M$429.9M2.15×
Peloton Therapeutics, Inc.Series A$13.7M$423.0M2.11×
Seahorse Bioscience IncSeries A$20.7M$410.2M2.05×
Stemgent, Inc.Series A$37.9M$408.5M2.04×
CMI HOLDING Co INC this companySeries A$8.8M$23.5M0.12×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$8.1M2009-07-13$37.0M$294.3M90%
Series A$650K2010-02-23$3.0M$23.5M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$8.1M2009-07-13
    • First recorded raise — entered as Series A.
  2. Series A$650K2010-02-23
    • Came back fast: 7 mo vs the ~14 mo sector norm.
    • Round 12.5× smaller than the prior — bridge or down round.
Intelligence
2010 ~Q4
Modeled next raise · ~7mo cadence
$650K
Modeled next size est.range $650K$1.0M
0.1×
Last step-up
$14.3M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
William M. Ashbaugh1 other2009-07
Albert M. Davis2009-07
David Hernon2009-07
David Jay Hernon2010-02
James O'Donnell2009-07
Jeffrey Jay Blanchard2010-02
Richard Jay Kimmey2009-07
Suresh Jay Reddy2010-02
Suresh Reddy2009-07
Registry & provenance

CMI HOLDING Co INC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1173951
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
IMMvention Therapeutix, Inc.BiotechnologySeries A$8.9M$21.9Msame sector · same stage
AutoIVF, Inc.BiotechnologySeries A$8.6M$17.4Msame sector · same stage
Cnsbio IncBiotechnologySeries A$9.1M$27.1Msame sector · same stage
SmartFlow Technologies, Inc.BiotechnologySeries A$8.4M$21.7Msame sector · same stage
Visgenx, Inc.BiotechnologySeries A$9.2M$24.4Msame sector · same stage
PATH EX, Inc.BiotechnologySeries A$8.3M$29.0Msame sector · same stage
Cytimmune Sciences IncBiotechnologySeries A$9.3M$29.1Msame sector · same stage
SkinJect, Inc.BiotechnologySeries A$8.3M$19.6Msame sector · same stage
Frequently asked
How much funding has CMI HOLDING Co INC raised?
CMI HOLDING Co INC has raised approximately $8.8M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is CMI HOLDING Co INC's estimated valuation?
Provath's modeled valuation for CMI HOLDING Co INC is approximately $23.5M (modeled range $709K–$127.8M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is CMI HOLDING Co INC at?
CMI HOLDING Co INC's latest modeled financing stage is Series A. Its most recent recorded round closed around Tue Feb 23.
What does CMI HOLDING Co INC do and where is it based?
CMI HOLDING Co INC operates in the Biotechnology sector, based in RICHARDSON.
Explore related

See where CMI HOLDING Co INC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at CMI HOLDING Co INC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.